Sota Jurgen, Gentileschi Stefano, Perfetti Maria Orsetta, Frediani Bruno, Tosi Gian Marco, Cantarini Luca, Fabiani Claudia
Rheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Ophthalmol Ther. 2021 Dec;10(4):1129-1135. doi: 10.1007/s40123-021-00387-6. Epub 2021 Aug 30.
To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behçet's syndrome (BS)-related uveitis.
Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retrospectively collected and analyzed.
Complete control of uveitis was observed in all 16 eyes without relapses during follow-up. The number of relapses 12 months prior to SB5 initiation and at last follow-up was 100 and 0 per 100 patients/year, respectively (p = 0.010). At baseline, four eyes had active retinal vasculitis, whereas at 3 months and at last follow-up, retinal vasculitis had resolved in all of them (p = 0.018). Median visual acuity did not vary significantly between baseline and last follow-up visit (p = 0.109). No ocular complications emerged during treatment.
SB5 is effective in the treatment of BS-related non-anterior uveitis. It reduces uveitis relapses and controls retinal vasculitis while allowing preservation of visual acuity.
评估阿达木单抗生物类似药SB5治疗白塞病（BS）相关葡萄膜炎的疗效。
回顾性收集并分析8例患有活动性非前葡萄膜炎和/或全身性未控制疾病或改用SB5治疗的BS患者（16只眼）的数据。
随访期间，所有16只眼的葡萄膜炎均得到完全控制，无复发。开始使用SB5前12个月和最后一次随访时的复发率分别为每100患者/年100次和0次（p = 0.010）。基线时，4只眼有活动性视网膜血管炎，而在3个月和最后一次随访时，所有这些眼的视网膜血管炎均已消退（p = 0.018）。基线和最后一次随访时的中位视力无显著差异（p = 0.109）。治疗期间未出现眼部并发症。
SB5治疗BS相关非前葡萄膜炎有效。它可减少葡萄膜炎复发并控制视网膜血管炎，同时保留视力。
